Your SlideShare is downloading. ×
  • Like
Art Of Breast Cancer
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Art Of Breast Cancer

  • 565 views
Published

ART3, frequently overexpressed in triple negative breast cancer, is a novel diagnostic marker candidate for aggressive, poor prognosis breast cancer

ART3, frequently overexpressed in triple negative breast cancer, is a novel diagnostic marker candidate for aggressive, poor prognosis breast cancer

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
565
On SlideShare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
13
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Triple negative breast cancer (BC) is an aggressive, poor-prognosis of breast cancer for which a clear clinical need exists because this sub-type of BC is refractory to hormone-therapy and herceptin.
    Meta-analysis of 3 independent breast cancer data sets demonstrates that triple negative breast cancer, which does not express the traditional markers of BC including ESR, PGR, and Her2/Neu, contains significantly elevated levels of ART3 mRNA. Hence, ART3 is a novel candidate marker for triple negative BC.
    No previously published data about ART3 in triple negative breast cancer exist. I carried out the current BC meta-analysis on data produced by unrelated whole-genome expression technologies. I did so in order to reduce the chance of technology-specific errors. Please use the GEO IDs in the above table to find the specific data sources at GEO website.
    -MehisPold, M.D.
    E-mail: mehisp@hotmail.com
    Copyright © Eomix, Inc.